The findings presented in this article complement a recent study evidencing therapeutic efficacy of HDAC inhibitors in a Tsc1−/−‐driven mouse model of lymphangiosarcoma.[33] HDAC inhibitors present an opportune class of molecules for pursuit due to the wide variety of compounds already approved for clinical use. The gene discussed is TSC1; the disease is lymphangiosarcoma.